ARHGAP42P2

Across TCGA pan-cancer cohorts, ARHGAP42P2 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARHGAP42P2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ARHGAP42P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGAP42P2 is over-expressed in tumor, although a few such as READ show the opposite, repressed pattern.

KIRC, BRCA, and PRAD are the cancer types where ARHGAP42P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGAP42P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.055	<.001	8	view →
BRCA	All	All	+0.104	.001	4	view →
PRAD	All	All	+0.100	.001	2	view →
STAD	Male	All	+0.019	.016	2	view →
READ	All	All	−0.058	.033	1	view →
THCA	All	III,IV	+0.031	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARHGAP42P2–KIRC

Open the KIRC breakdown →